- Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon MutationsJie, G. -L.; Zheng, M. -M.; Tu, H. -Y.; Yin, K.; Zhou, Q.; Yang, J. -J.; Zhang, X. -C.; Wang, B. -C.; Chen, H. -J.; Jiang, B-Y.; Li, Y. -S.; Wu, Y. -L.
- High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVEFan, Y.; Zhu, J.; He, J.; Zhou, R.; Chen, J.; Han, G.; Ren, B. Y.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- Matched Targeted Therapy by cfDNA of CSF Beyond Leptomeningeal Metastases Progression Upon Osimertinib in EGFR-Mutated NSCLC PatientsZheng, M.; Li, Y.; Tu, H.; Sun, H.; Yin, K.; Yang, J.; Zhang, X.; Zhou, Q.; Wu, Y.
期刊论文
Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases
1被引9阅读
